

1 December 2014

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement - Appointment of Director

In accordance with rule 6.17 (2) of Section IIA of the NSX Listing and Business Rules, IQX Limited (NSX:IQX) today announce the following change to its Board, with effect from 25 November 2014.

IQX Limited is pleased to announce the appointment of Dr George Syrmalis, as Executive Director and Chief Executive Officer. Dr Syrmalis is the current CEO, and has been at the helm for many of the Company's significant milestone moments.

Dr Syrmalis is trained in Nuclear Medicine-radiation Immunology and has substantial experience in leading listed companies as either Chairman or CEO. Dr Syrmalis' skills and experience will prove invaluable to the Board and the Company.



Kelvin Boateng

Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQX's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQX Limited

IQX Ltd is a specialist life science investment organisation,.

Sydney: 222 Clarence Street, Sydney, NSW 2000, Australia *Phone: +61 2 8239 5400 *Fax: +61 2 8362 9325
New York: 200 Park Avenue, Suite 1700, New York City, NY, USA 10166 •
London: 5 Harbour Exchange, Harbour Exchange Square, Canary Wharf E14 9GE UK•